ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
7,962.30
0.18%
S&P ASX All Technology
3,635.00
0.14%
Brent Oil
69.855
0.19%
US Dollar vs AUD
1.58178
-0.57%
Bitcoin
82,160.23
1.96%
Pepperstone
Advertisement
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE

  6. Merck and Co Inc (MRK) Share Price

Merck and Co Inc

Merck and Co Inc (MRK)

Marks Electrical Group Plc
Merck CDR
Merck KGAA
94.65
0.65
(0.69%)
Closed 10 March 7:00AM
Delayed by 15 minutes
94.90
0.25
(0.26%)
After Hours: 11:58AM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
94.90
Bid
-
Offer
-
Volume
23,984,834
93.85 Day's Range 97.31
81.04 52 Week Range 134.63
Market Cap
239.721B
Previous Close
94.00
Open
94.26
Last Trade
18
@
94.72
Last Trade Time
Financial Volume
US$ 2,290,563,591
VWAP
95.5005
Average Volume (3m)
14,081,854
Shares Outstanding
2,526,036,240
Dividend Yield
3.41%
PE Ratio
13.97
Earnings Per Share (EPS)
6.78
Revenue
64.17B
Net Profit
17.12B

About Merck and Co Inc

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vacci... Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.merck.com
Headquarters
West Trenton, New Jersey, USA
Founded
-
Merck and Co Inc is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker MRK. The last closing price for Merck was US$94. Over the last year, Merck shares have traded in a share price range of US$ 81.04 to US$ 134.63.

Merck currently has 2,526,036,240 shares in issue. The market capitalisation of Merck is US$237.45 billion. Merck has a price to earnings ratio (PE ratio) of 13.97.

Ask ADVFN Intelligence (AI)

Merck (MRK) Options Flow Summary

MRK Options Flow

Overall Flow

Bullish

Net Premium

5M

Calls / Puts

354.17%

Buys / Sells

116.33%

OTM / ITM

53.52%

Sweeps Ratio

0.00%

MRK Latest News

More News

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Edgar (US Regulatory)
26 February 2025
MRK (0.69%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
21 February 2025
MRK (0.69%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
20 February 2025
MRK (0.69%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
14.254.6883618312290.6595.3690.51370331392.96453571CS
47.48.4571428571487.595.3681.041705052488.15697978CS
12-6.35-6.27160493827101.25102.9781.041408185493.21038195CS
26-18.22-16.1067892504113.12119.3881.041227491099.51161912CS
52-28.32-22.9832819348123.22134.6381.0410547130110.01950607CS
15617.8623.182762201577.04134.6376.089291810104.60258866CS
26016.921.666666666778134.6365.251020088892.52970378CS

MRK - Frequently Asked Questions (FAQ)

What is the current Merck share price?
The current share price of Merck is US$ 94.90
How many Merck shares are in issue?
Merck has 2,526,036,240 shares in issue
What is the market cap of Merck?
The market capitalisation of Merck is USD 237.45B
What is the 1 year trading range for Merck share price?
Merck has traded in the range of US$ 81.04 to US$ 134.63 during the past year
What is the PE ratio of Merck?
The price to earnings ratio of Merck is 13.97
What is the cash to sales ratio of Merck?
The cash to sales ratio of Merck is 3.73
What is the reporting currency for Merck?
Merck reports financial results in USD
What is the latest annual turnover for Merck?
The latest annual turnover of Merck is USD 64.17B
What is the latest annual profit for Merck?
The latest annual profit of Merck is USD 17.12B
What is the registered address of Merck?
The registered address for Merck is 820 BEAR TAVERN ROAD, WEST TRENTON, NEW JERSEY, 08628 1021
What is the Merck website address?
The website address for Merck is www.merck.com
Which industry sector does Merck operate in?
Merck operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PNSTPinstripes Holdings Inc
US$ 0.102
(115.64%)
464.13k
WLYBJohn Wiley and Sons Inc
US$ 44.79
(19.92%)
161
AMRCAmeresco Inc
US$ 11.08
(19.27%)
1.97M
GAPGap Inc
US$ 23.15
(18.84%)
30.17M
KUKEKuke Music Holding Limited
US$ 0.2273
(18.57%)
3.35M
BBAIBigBear ai Holdings Inc
US$ 3.37
(-19.76%)
78.65M
GCOGenesco Inc
US$ 27.13
(-16.27%)
1.23M
IOTSamsara Inc
US$ 35.38
(-15.52%)
13.19M
EVCEntravision Communications Corp
US$ 1.76
(-15.38%)
1.41M
AKAaka Brands Holding Corp
US$ 13.40
(-11.90%)
17.99k
FFord Motor Company
US$ 9.895
(2.97%)
150.64M
HPEHewlett Packard Enterprise Co
US$ 16.011
(-10.85%)
81.95M
BBAIBigBear ai Holdings Inc
US$ 3.37
(-19.76%)
78.65M
NUNu Holdings Ltd
US$ 10.815
(1.55%)
63.83M
BTEBaytex Energy Corporation
US$ 2.03
(3.05%)
57.91M

MRK Discussion

View Posts
BLACKBIRDSR-71 BLACKBIRDSR-71 6 months ago
SPECULATION OF ALL CANCER NATIONS BREAKTHROUGH DECLARED
👍️0
BLACKBIRDSR-71 BLACKBIRDSR-71 6 months ago
Cancer breakthrough in the clinic broski Rnaz https://www.eurekalert.org/news-releases/1055915
👍️0
ZLAZARUS ZLAZARUS 7 months ago
Picked up a few hundred shares today
👍️0
DewDiligence DewDiligence 7 months ago
MRK 2Q24 results:

https://www.businesswire.com/news/home/20240730509685/en
👍️0
DewDiligence DewDiligence 8 months ago
MRK’s RSV prophylactic, Clesrovimab meets_all_endpoints_in_phase-2/3_trial:

https://www.businesswire.com/news/home/20240723229019/en

If approved, Clesrovimab will compete against GSK’s Beyfortus.

Beyfortus and Clesrovimab are effective at preventing RSV for one season, but they do not confer lasting immunity. Patients taking these drugs are likely to contract RSV infection in a subsequent season, and hence the need for RSV treatments, such as those being developed by ENTA, is not diminished.
👍️0
ShadowVolcano37 ShadowVolcano37 8 months ago
MRK is doing really well. Wish I invested two years ago. Personalized Immunotherapy is going to be a huge thing very soon. So maybe it's not too late.
👍️0
DewDiligence DewDiligence 8 months ago
ACIP endorses MRK’s Capvaxive pneumococcal vaccine for certain groups—creating parity with PFE’s Prevnar-13 for adult market:

https://www.businesswire.com/news/home/20240627540619/en
• Adults 65 years of age and older who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown;

• Adults 19-64 years of age with certain underlying medical conditions or other risk factors who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown;

• Adults 19 years of age and older who have started their pneumococcal vaccine series with PCV13 (pneumococcal 13-valent conjugate vaccine) [PFE’s Prevnar-13] but have not received all recommended PPSV23 [MRK’s Pneumovax]…;

• Additionally, shared clinical decision-making is recommended regarding use of a supplemental dose of CAPVAXIVE for adults 65 years of age and older who have completed their vaccine series with both PCV13 [Prevnar-13] and PPSV23 [Pneumovax]. These ACIP recommendations are essentially the same as the CDC’s existing recommendations for PFE’s Prevnar-20, and hence they should allow MRK’s Capvaxive to gain a meaningful share in the adult portion of the pneumococcal vaccine market. PFE has had an overwhelming (>90%) share of this market in the US because MRK’s other conjugated pneumococcal vaccine, Vaxneuvance, received a less favorable recommendation from the CDC than PFE’s Prevnar-13.

Please see #msg-166441188 and #msg-172452293 for related info.
👍️0
DewDiligence DewDiligence 9 months ago
FDA approves MRK’s Capvaxive—(f/k/a V116)—pneumococcal vaccine for adults:

https://www.businesswire.com/news/home/20240614126575/en

With this approval, MRK should finally get a decent share of the market for adult pneumococcal vaccines, where PFE’s Prevnar franchise has long been dominant.

Please see #msg-173458310 and #msg-172452293 for related info.
👍️0
avxl_going_long avxl_going_long 10 months ago
https://www.sciencetimes.com/articles/50071/20240508/anavex-life-sciences-alzheimers-treatment-brings-hope-to-millions.htm
👍️0
axelvento axelvento 12 months ago
https://www.onclive.com/view/pembrolizumab-plus-concurrent-crt-meets-os-end-point-in-high-risk-locally-advanced-cervical-cancer
👍️0
axelvento axelvento 12 months ago
KEYTRUDA plus CRT is the first immunotherapy-based regimen to demonstrate a statistically significant improvement in OS in these patients

KEYNOTE-A18, also known as ENGOT-cx11/GOG-3047, is a randomized, double-blind Phase 3 trial

https://www.biospace.com/article/releases/merck-s-keytruda-pembrolizumab-plus-chemoradiotherapy-crt-significantly-improved-overall-survival-os-versus-crt-alone-in-patients-with-newly-diagnosed-high-risk-locally-advanced-cervical-cancer/?keywords=pancreatic+cancer+phase+3
👍️0
Monksdream Monksdream 1 year ago
MRK new 52 week high
👍️0
fly123 fly123 1 year ago
Bought 11% of EVAX
👍️0
snoopycomic snoopycomic 1 year ago
Why Red fonts?
👍️0
DewDiligence DewDiligence 2 years ago
MRK reports 2Q23 results…

PR:
https://www.businesswire.com/news/home/20230801830764/en

Reuters:
https://finance.yahoo.com/news/1-merck-beats-quarterly-sales-104937970.html Merck & Co raised its full-year revenue forecast on Tuesday as second-quarter sales of its top-selling products, cancer immunotherapy Keytruda and human papillomavirus (HPV) vaccine Gardasil, sailed past Wall Street estimates.

Merck said Keytruda sales for the quarter jumped 19% to $6.3 billion, surpassing analysts' average estimate of $5.9 billion.

…Sales of Gardasil…surged 47% to $2.5 billion, also well above Wall Street estimates of $2.1 billion. MRK sharply lowered 2023 non-GAAP EPS guidance due to a $10.2B charge ($4.02/sh) relating to in-process R&D from the acquisition of RXDX (#msg-171696785). The new guidance range is $2.95-3.05.
👍️0
DewDiligence DewDiligence 2 years ago
MRK’s V116 shows non-inferiority to Prevnar-20 in two phase-3 trials (one for pneumococcal-vaccine naïve patients and one for patients who received a prior pneumococcal vaccine):

https://www.businesswire.com/news/home/20230727120762/en

V116 is a 21-valent pneumococcal vaccine intended for the adult market only. PFE’s Prevnar-20 currently owns virtually the entire adult market for pneumococcal vaccines because CDC/ACIP’s recommendations give preferential treatment to Prevnar-20 vs MRK’s 15-valent V114 (a/k/a Vaxneuvance) (#msg-166441188).

The V116 results announced today put MRK back in the ballgame for the adult segment of the market.

See #msg-168548763 for related info.
👍️0
DewDiligence DewDiligence 2 years ago
MRK sues US over IRA drug-price “negotiation”:

https://www.wsj.com/articles/merck-challenges-u-s-governments-new-powers-to-negotiate-drug-prices-127d4b0c Drugmaker Merck & Co. filed a lawsuit on Tuesday challenging the U.S. government’s plan to negotiate drug prices, saying it is unconstitutional.

Drugmakers were expected to file lawsuits challenging the program, especially as Medicare neared the date later this year when it began naming some drugs it would target for price negotiations.

Among the drugs that analysts expected to face price negotiations are Merck’s top-selling product, the cancer immunotherapy Keytruda.

Merck’s complaint takes issue with the negotiation program’s enforcement rules, which include the power to levy an excise tax of up to 95% of a drug’s U.S. sales if a pharmaceutical company refuses to sell the drug to Medicare patients. Merck said the tax would be coercive and violate the constitution’s Fifth Amendment ban on private property being taken for public use without just compensation. [The so-called “takings” clause.]

Merck also said the law would force companies to agree that the government-mandated prices are “fair,” violating its free speech rights under the First Amendment. For biotech investors, there’s a lot riding on the outcome of this lawsuit and related cases.

Want more details? See https://www.cms.gov/files/document/medicare-drug-price-negotiation-program-initial-guidance.pdf (91 pages).
👍️0
DewDiligence DewDiligence 2 years ago
MRK’s ASCO lineup:

https://finance.yahoo.com/news/merck-present-extensive-research-demonstrating-104500565.html
👍️0
DewDiligence DewDiligence 2 years ago
MRK reports 1Q23 results—raises non-GAAP EPS guidance:

https://finance.yahoo.com/news/merck-announces-first-quarter-2023-103000788.html

https://finance.yahoo.com/news/merck-earnings-better-expected-keytruda-103855413.html

2023 non-GAAP EPS guidance was raised to $6.88-7.00 (from $6.80-6.95).
👍️0
DewDiligence DewDiligence 2 years ago
MRK acquires RXDX for $10.8B…

PR:
https://www.merck.com/news/merck-strengthens-immunology-pipeline-with-acquisition-of-prometheus-biosciences-inc/

CC slides:
https://s21.q4cdn.com/488056881/files/doc_presentations/2023/04/Acquisition-of-Prometheus-Biosciences-Investor-Event-Slides-FINAL.pdf
👍️0
DewDiligence DewDiligence 2 years ago
A Delaware judge ruled today that MRK remains liable for talc lawsuits relating to Dr. Scholl’s foot powder, even though MRK sold its OTC- healthcare business to Bayer in 2014:

https://finance.yahoo.com/news/bayer-defeats-merck-lawsuit-over-215120183.html

MRK inherited Dr. Scholl’s in the 2009 takeover of Schering-Plough.
👍️0
DewDiligence DewDiligence 2 years ago
Keytruda shows statsig-superior PFS as addend to chemo in Stage-III/IV (or recurrent) endometrial cancer:

https://www.businesswire.com/news/home/20230327005147/en

The HR for PFS was 0.54 in the pMMR subgroup and 0.30(!) in the dMMR subgroup.

The OS results are not disclosed in the PR, so they are presumably not mature. (OS was a secondary endpoint.)
👍️0
DewDiligence DewDiligence 2 years ago
EMA rejects MRK’s MAA for Molnipiravir:

https://www.businesswire.com/news/home/20230223006077/en Merck and Ridgeback Biotherapeutics today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the refusal of the marketing authorization for LAGEVRIO (molnupiravir) for the treatment of certain adults who have been diagnosed with COVID-19 in the European Union (EU). Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion. The appeal would seem to be fruitless. Molnupiravir is simply a bad drug that doesn’t deserve (non-emergency) marketing authorization.
👍️0
DewDiligence DewDiligence 2 years ago
MRK 4Q22 results—2023 guidance:

https://s21.q4cdn.com/488056881/files/doc_financials/2022/q4/Merck-News-Release-02-02-23-Merck-Announces-4Q-and-FY-2022-Financial-Results.pdf

2023 guidance for non-GAAP EPS is $6.80-6.95; at the midpoint, this is an 8% decline from 2022’s $7.48.

CC slides:
https://s21.q4cdn.com/488056881/files/doc_financials/2022/q4/Q4-2022-Merck-Earnings-Deck-(Final).pdf

Prepared remarks:
https://s21.q4cdn.com/488056881/files/doc_financials/2022/q4/Q4-2022-Merck-Earnings-Prepared-Remarks-(Final).pdf
👍️0
DewDiligence DewDiligence 2 years ago
FDA approves Keytruda for adjuvant NSCLC following adjuvant treatment with platinum chemo:

https://www.businesswire.com/news/home/20230127005078/en

Keytruda’s HR for DFS (compared to placebo) was 0.73 [95% CI: 0.60-0.89]. This is slightly better than the HR=0.76 that MRK reported when the KEYNOTE-091 trial reported in Mar 2022 (#msg-168241140); I do not know the reason for the discrepancy.

Curiously, in an exploratory analysis of patients (n=167) who did not receive adjuvant chemo, Keytruda’s HR for DFS (relative to placebo) was 1.25 (i.e. the Keytruda arm did worse than placebo), but the 95% confidence interval was wide [0.76-2.05].
👍️0
extrooper extrooper 2 years ago
That would be the best , most productive purchase they could ever make , but Merck mgt is too stupid. They try to build equivalent to DCVax with every asinine purchase they make. Maybe a new mgt team at Merck with common sense, would get DCVax , the most incredible advancement in GBM and immunology in history.
👍️0
DewDiligence DewDiligence 2 years ago
Keytruda fails again in prostate cancer—one of the few cancer indications where it has not seen a positive outcome:

https://www.businesswire.com/news/home/20230124006084/en/Merck-Announces-KEYNOTE-991-Trial-Evaluating-KEYTRUDA%C2%AE-pembrolizumab-Plus-Enzalutamide-and-Androgen-Deprivation-Therapy-in-Patients-With-Metastatic-Hormone-Sensitive-Prostate-Cancer-to-Stop-for-Futility Merck…today announced that it will stop the Phase 3 KEYNOTE-991 trial investigating KEYTRUDA…in combination with enzalutamide and androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC).

…At the interim analysis, KEYTRUDA in combination with enzalutamide [Xtandi] and ADT did not demonstrate an improvement in overall survival (OS) or radiographic progression-free survival (rPFS), the trial’s dual primary endpoints, compared to placebo plus enzalutamide and ADT. This is Keytruda’s third recent phase-3 in prostate cancer. In the KEYNOTE-921 trial, which reported results in Aug 2021, Keytruda failed to show a statsig benefit when added to chemo in CRPC (#msg-169574792). In the KEYLINK-010 study, which reported results in Mar 2022, the combination of Keytruda and Lynparza (a PARP inhibitor) failed to show a statisig benefit compared to Xtandi or Zytiga in mCPRC refractory to chemo and either of Xtandi or Zytiga (https://www.clinicaltrials.gov/ct2/show/NCT03834519 ).

Keytruda is a great drug, but it’s not invincible.
👍️0
Pattyloco Pattyloco 2 years ago
Why
👍️0
DewDiligence DewDiligence 2 years ago
The MRK-SGEN deal reputed to be nearly done last summer (#msg-169332904) can probably be dismissed after MRK’s ADC collaboration with China’s Kelun-Biotech today:

https://finance.yahoo.com/news/merck-kelun-biotech-announce-exclusive-114500834.html
👍️0
DewDiligence DewDiligence 2 years ago
MRK/MRNA cancer vaccine shines in adjuvant melanoma (RFS HR=0.56):

https://www.accesswire.com/731571/Moderna-and-Merck-Announce-mRNA-4157V940-an-Investigational-Personalized-mRNA-Cancer-Vaccine-in-Combination-with-KEYTRUDAR-pembrolizumab-Met-Primary-Efficacy-Endpoint-in-Phase-2b-KEYNOTE-942-Trial …the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA…demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of recurrence-free survival (RFS) versus KEYTRUDA alone for the adjuvant treatment of patients with stage III/IV melanoma following complete resection.

Adjuvant treatment with mRNA-4157/V940 in combination with KEYTRUDA reduced the risk of recurrence or death by 44% (HR=0.56 [95% CI, 0.31-1.08]; one-sided p-value=0.0266) compared with KEYTRUDA alone. Note: If this had been a phase-3 trial, it would’ve been considered a failure since the standard cutoff for a one-sided p-value is 0.025. For a phase-2b, however, these results are just fine.
👍️0
DewDiligence DewDiligence 2 years ago
MRK acquires IMGO for $36.00/sh cash—a 107% premium to Friday’s close:

https://finance.yahoo.com/news/merck-acquire-imago-biosciences-inc-114500059.html

The nominal deal value is $1.35B. The buyout price is a 125% premium to IMGO’s IPO price 16 months ago (#msg-164945919).
👍️0
DewDiligence DewDiligence 2 years ago
I would take the other side of that bet!
👍️0
Pattyloco Pattyloco 2 years ago
Ehhhhh seems a lot more likely today
👍️0
DewDiligence DewDiligence 2 years ago
Unlikely, haha.
👍️0
Pattyloco Pattyloco 2 years ago
NWBO next purchase of Merck?
👍️0
DewDiligence DewDiligence 2 years ago
MRK 3Q22 CC slides:

https://s21.q4cdn.com/488056881/files/doc_financials/2022/q3/Q3-2022-Merck-Earnings-Deck-(Final).pdf
👍️0
DewDiligence DewDiligence 2 years ago
MRK 3Q22 results:

https://finance.yahoo.com/news/merck-announces-third-quarter-2022-103000305.html
👍️0
DewDiligence DewDiligence 2 years ago
MRK exercises option_to_commercialize MRNA cancer vaccine:

https://www.accesswire.com/720004/Merck-and-Moderna-Announce-Exercise-of-Option-by-Merck-for-Joint-Development-and-Commercialization-of-Investigational-Personalized-Cancer-Vaccine

https://finance.yahoo.com/news/1-merck-opts-jointly-develop-113551661.html

MRNA receives $250M in immediate cash from MRK’s opt-in.
👍️0
DewDiligence DewDiligence 2 years ago
Sotatercept phase-3 in PAH hits primary endpoint:

https://finance.yahoo.com/news/merck-announces-positive-top-line-104500840.html

Sotatercept is the drug MRK picked up in the $11.5B XLRN acquisitions last year (#msg-166156870).
👍️0
DewDiligence DewDiligence 2 years ago
Lagevrio misses_primary_endpoint_in_large_Oxford_U_trial:

https://ca.finance.yahoo.com/news/merck-ridgeback-biotherapeutics-clinical-non-235000071.html The PANORAMIC study, a UK-based clinical trial sponsored by the University of Oxford, included 25,783 participants who were randomized to open label treatment with LAGEVRIO plus usual care (n=12,821) or usual care alone (n=12,962); mean age of participants was 56.6 years. Primary outcome data were available in 25,000 (97%) participants. Nearly all (>98%) participants were vaccinated, with approximately 95% receiving three or more doses of a SARS-CoV-2 vaccine.

In the preliminary analysis, the primary endpoint of reduction of hospitalizations and deaths within 28 days of randomization, compared to usual care, was not met; 0.8% of patients in both the LAGEVRIO group (n=103/12,516) and the usual care group (n=96/12,484) were hospitalized or died in the first 28 days. Separately, in a retrospective study based on electronic medical records of high-risk patients in Israel, Lagevrio showed a benefit in reducing hospitalizations and death in the patients age 65+ but not in patients age 40-64.

Bottom line: Legevrio (molnupiravir) remains a poor choice for treating COVID. It is being prescribed only when Paxlovid is either unavailable or contra-indicated due to drug-drug interactions (from ritonavir).
👍️0
DewDiligence DewDiligence 2 years ago
FDA allows some Islatravir trials to_resume_at_a lower dose:

https://finance.yahoo.com/news/merck-initiate-phase-3-clinical-104500524.html
👍️0
DewDiligence DewDiligence 2 years ago
Keytruda narrowly_misses_statsig OS/PFS as_addend_to Lenvina in_ first-line HCC:

https://finance.yahoo.com/news/merck-eisai-present-results-phase-063000955.html

In the final analysis of the trial, there was a trend toward improvement for one of the study’s dual primary endpoints, overall survival (OS), for patients treated with KEYTRUDA plus LENVIMA versus LENVIMA monotherapy; however, the results did not meet statistical significance per the pre-specified statistical plan (HR=0.84 [95% CI: 0.71-1.00]; p=0.0227). The median OS was 21.2 months (95% CI: 19.0-23.6) for KEYTRUDA plus LENVIMA and 19.0 months (95% CI: 17.2-21.7) for LENVIMA monotherapy.

Additionally, treatment with KEYTRUDA plus LENVIMA resulted in a trend toward improvement in the trial’s other dual primary endpoint of progression-free survival (PFS) versus LENVIMA monotherapy; however, the results did not meet the pre-specified threshold at the first interim analysis for statistical significance (HR=0.87 [95% CI: 0.73-1.02]; p=0.0466). These results were presented at ESMO.
👍️0
TechandBio TechandBio 3 years ago
Merck snatched up ROR1 veslobio for 2.75 Billion I think they may try and Buy ONCT better acting drug partnered with ABBV ibrutinib the combo works 50% better than the drug alone. Pcyc ibrutinib now ABBV is going to do 9.5-10 Billion in sales next year. I think Merck might buy ONCT more data further along in trials very robust pipeline. ROR1 expression on many tumor types
• Potential safety and efficacy advantages
• MK-2140 ADC data at ASH 2021: no apparent off-
tumor, on-target ROR1 toxicities.
ROR1 Expressed on Multiple
Solid and Liquid Tumor's
MCL 95%
CLL 95%
Uterus 96%
Lymphoma 90%
Prostate 90%
Skin 89%
Insiders have been buying it up just broke the 50 day moving average. I think Merck might come in to add to there Ror1 portfolio.
https://www.fiercebiotech.com/biotech/boehringer-inks-1-5b-nbe-buyout-joining-merck-ror1-adc-race

$MRK
👍️0
DewDiligence DewDiligence 3 years ago
Keytruda fails phase-3 in CRPC:

https://www.businesswire.com/news/home/20220803005334/en Merck…today announced that the Phase 3 KEYNOTE-921 trial evaluating KEYTRUDA in combination with chemotherapy (docetaxel) compared to chemotherapy alone did not meet its dual primary endpoints of overall survival (OS) and radiographic progression-free survival (rPFS) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). In the study, there were modest trends toward an improvement in both OS and rPFS for patients who received KEYTRUDA plus chemotherapy compared with chemotherapy alone; however, these results did not meet statistical significance per the pre-specified statistical plan. Keytruda will soon overtake Humira as the biggest-selling non-COVID drug from any company; however, it is not invincible.
👍️0
DewDiligence DewDiligence 3 years ago
FDA approves MRK’s pneumococcal vaccine, Vaxneuvance for infants/children:

https://finance.yahoo.com/news/u-fda-approves-merck-vaxneuvance-104500312.html

Vaxneuvance was already FDA-approved for adults (#msg-164961310), but I don’t think Vaxneuvance will compete effectively with PFE’s Prevnar-20, which has broader coverage of pneumococcal serotypes and a simpler (one-shot) treatment course (#msg-166441188).

PFE's Prevnar-20 is FDA approved for adults, but is not yet approved for infants/children, so MRK does have a head start in the pediatric market.

MRK pays PFE a royalty of 7.25% on worldwide Vaxneuvance sales during 2022-2026 and a 2.5% royalty during 2027-2035 (#msg-166075692).
👍️0
Agoura Guy Agoura Guy 3 years ago
WHAT ARE YOU TALKING ABOUT??? COVID-19 IS JUST RENAMED INFLUENZA.... ITS A TOTAL SCAM!!!!!

BIG PHARMA ARE CRIMINALS DUPING THE PUBLIC!!!!!!!!

ENOUGH WITH THE MINDLESS HYSTERIA ALREADY!!!!!!!

👍️ 1
Lowjack Lowjack 3 years ago
Pay attention, looks like we have a change in the last immune escape variants. They may have also become more heat tolerant, or more stupid monkeys are hanging out with eachother. Uptick in Delta.


Don't forget to order your Ivermectin while everyone is distracted by idiot Joe.
👍️0
DewDiligence DewDiligence 3 years ago
MRK slides from ASCO webcast:

https://s21.q4cdn.com/488056881/files/doc_events/2022/06/ASCO-2022-Slide-Presentation-Final.pdf
👍️0
DewDiligence DewDiligence 3 years ago
Synopsis of (anti-LAG-3) favezelimab data from ASCO abstract:

https://www.biopharmadive.com/news/asco-merck-favezelimab-lag3-hodgkin-trial/624457/

Favezelimab might eventually compete with BMY’s Opdualag (#msg-168259768), but it has a long way to go.

Please see #msg-168259803 and https://twitter.com/DewDiligence/status/1395141087413538822 for related info.
👍️0
DewDiligence DewDiligence 3 years ago
MRK 1Q22 results:

https://finance.yahoo.com/news/merck-announces-first-quarter-2022-103000567.html

https://finance.yahoo.com/news/merck-quarterly-profit-tops-expectations-104117628.html
👍️0

Your Recent History

NYSE
MRK
Merck
TSXV
IXI
Indigo Explorations
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads